Microdosing magic mushrooms: brain boost or placebo?
NCT ID NCT07449351
First seen Mar 09, 2026 · Last updated Jun 21, 2026 · Updated 20 times
Summary
This pilot study from Yale University will test whether very low, non-hallucinogenic doses of psilocybin (the active compound in magic mushrooms) can improve mood, thinking, and quality of life. Twenty healthy adults with no prior psychedelic use will take either psilocybin or a placebo three times a week for 30 days. Researchers will measure changes in memory, attention, emotional well-being, and brain activity using MRI scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSYCHEDELIC MICRODOSING EFFECTS ON MOOD, COGNITION, SUBJECTIVE WELL-BEING AND MRI are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Olin Neuropsychiatry Research Center
Hartford, Connecticut, 06106, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
psilocybin (very low dose, 2.0 mg)
What this could lead to
If it works, this could point toward a safe, non-hallucinogenic way to boost mood and mental sharpness in daily life.
What could go wrong
This is a very early, small pilot study with only 20 people. It may not show clear benefits, and results may not apply to the general public.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.